QR Kodea

Efficacy and toxicity of low-doses versus standard-dose enzalutamide in advanced prostate cancer: a real-world study with implications for cancer prevention/interception

Abstract Background Enzalutamide at standard doses (160 mg/day) is effective in advanced prostate cancer (PCa) but is associated with considerable adverse events (AEs) and high financial costs. Preliminary reports suggest that low/intermediate doses (≤80 mg/day) retain efficacy while reducing toxici...

Deskribapen osoa

Gorde:
Egile Nagusiak: Martino Oliva, Monica Boitano, Alessio Carbone, Irene Maria Briata, Tania Buttiron Webber, Davide Corradengo, Carlo Introini, Matteo Puntoni, Marco Ennas, Federico Germinale, Nicoletta Provinciali, Matteo Clavarezza, Alberto Gozza, Carlotta Defferrari, Mauro D’Amico, Howard L. Parnes, Andrea DeCensi
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMC 2025-12-01
Saila:BMC Cancer
Gaiak:
Adverse events
Dose optimization
Dose-Response relationship
Elderly patients
Enzalutamide
Fatigue
Sarrera elektronikoa:https://doi.org/10.1186/s12885-025-15396-y
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak